Role of the Endothelial-to-mesenchymal Transition in Renal Fibrosis of Chronic Kidney Disease

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2013 Feb 23

PMID 23430391

Citations 88

Authors

Jianhua He

Yong Xu

Daisuke Koya

Keizo Kanasaki

Affiliations

Soon will be listed here.

Abstract

All types of progressive chronic kidney disease (CKD) inevitably induce renal fibrosis, the hallmark of which is the activation and accumulation of a large number of matrix-producing fibroblasts or myofibroblasts. The activated fibroblasts or myofibroblasts are derived from diverse origins, such as residential fibroblasts, vascular pericytes, epithelial-to-mesenchymal transition (EMT), and bone marrow (circulating fibrocytes). Recently, endothelial-to-mesenchymal transition (EndMT) or endothelial-to-myofibroblast transition has also been suggested to promote fibrosis and is recognized as a novel mechanism for the generation of myofibroblasts. Similar to EMT, during EndMT, endothelial cells lose their adhesion and apical-basal polarity to form highly invasive, migratory, spindle-shaped, elongated mesenchymal cells. More importantly, biochemical changes accompany these distinct changes in cell polarity and morphology, including the decreased expression of endothelial markers and the acquisition of mesenchymal markers. This review highlights evidence supporting the important role of EndMT in the development of renal fibrosis in CKD and its underlying mechanisms, including novel biological significance of microRNA regulation.

Citing Articles

Store-Operated Ca Entry in Fibrosis and Tissue Remodeling.

Abdelnaby A, Trebak M Contact (Thousand Oaks). 2024; 7:25152564241291374.

PMID: 39659877 PMC: 11629433. DOI: 10.1177/25152564241291374.

Endothelial-mesenchymal transition in skeletal muscle: Opportunities and challenges from 3D microphysiological systems.

Francescato R, Moretti M, Bersini S Bioeng Transl Med. 2024; 9(5):e10644.

PMID: 39553431 PMC: 11561840. DOI: 10.1002/btm2.10644.

Novel dysregulated long non-coding RNAs in the acute kidney injury-to-chronic kidney diseases transition unraveled by transcriptomic analysis.

Puri B, Majumder S, Gaikwad A Pharmacol Res Perspect. 2024; 12(6):e70036.

PMID: 39549026 PMC: 11568611. DOI: 10.1002/prp2.70036.

Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.

Wang Z, Li L, Yang S, Li Z, Zhang P, Shi R Front Microbiol. 2024; 15:1470953.

PMID: 39444690 PMC: 11497467. DOI: 10.3389/fmicb.2024.1470953.

The molecular mechanisms of peptidyl-prolyl isomerase Pin1 and its relevance to kidney disease.

Wu S, Zou Y, Tan X, Yang S, Chen T, Zhang J Front Pharmacol. 2024; 15:1373446.

PMID: 38711994 PMC: 11070514. DOI: 10.3389/fphar.2024.1373446.

References

Kisanuki Y, Hammer R, Miyazaki J, Williams S, Richardson J, Yanagisawa M . Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001; 230(2):230-42. DOI: 10.1006/dbio.2000.0106. View

Pandit K, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson K . Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 182(2):220-9. PMC: 2913236. DOI: 10.1164/rccm.200911-1698OC. View

Cho M . Renal fibrosis. Korean J Pediatr. 2010; 53(7):735-40. PMC: 3004484. DOI: 10.3345/kjp.2010.53.7.735. View

Eddy A . Molecular basis of renal fibrosis. Pediatr Nephrol. 2001; 15(3-4):290-301. DOI: 10.1007/s004670000461. View

Barnes J, Glass Ii W . Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts. Contrib Nephrol. 2011; 169:73-93. DOI: 10.1159/000313946. View

Song H, Wang Q, Wen J, Liu S, Gao X, Cheng J . ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a. Int J Mol Sci. 2012; 13(2):2063-2077. PMC: 3292007. DOI: 10.3390/ijms13022063. View

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

Fafeur V, Terman B, Blum J, Bohlen P . Basic FGF treatment of endothelial cells down-regulates the 85-KDa TGF beta receptor subtype and decreases the growth inhibitory response to TGF-beta 1. Growth Factors. 1990; 3(3):237-45. DOI: 10.3109/08977199009043908. View

Ma L, Lu M, Schwartz R, Martin J . Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development. 2005; 132(24):5601-11. DOI: 10.1242/dev.02156. View

10.

Zeisberg E, Potenta S, Xie L, Zeisberg M, Kalluri R . Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007; 67(21):10123-8. DOI: 10.1158/0008-5472.CAN-07-3127. View

11.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-4. DOI: 10.1038/nature07511. View

12.

Li J, Huang X, Zhu H, Johnson R, Lan H . Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003; 63(6):2010-9. DOI: 10.1046/j.1523-1755.2003.00016.x. View

13.

Li J, Huang X, Zhu H, Oldfield M, Cooper M, Truong L . Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 2003; 18(1):176-8. DOI: 10.1096/fj.02-1117fje. View

14.

Medici D, Shore E, Lounev V, Kaplan F, Kalluri R, Olsen B . Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010; 16(12):1400-6. PMC: 3209716. DOI: 10.1038/nm.2252. View

15.

Boor P, Floege J . The renal (myo-)fibroblast: a heterogeneous group of cells. Nephrol Dial Transplant. 2012; 27(8):3027-36. DOI: 10.1093/ndt/gfs296. View

16.

Zeisberg E, Potenta S, Sugimoto H, Zeisberg M, Kalluri R . Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008; 19(12):2282-7. PMC: 2588112. DOI: 10.1681/ASN.2008050513. View

17.

Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A . E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010; 59(7):1794-802. PMC: 2889781. DOI: 10.2337/db09-1736. View

18.

Ramos C, Becerril C, Montano M, Garcia-de-Alba C, Ramirez R, Checa M . FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010; 299(2):L222-31. DOI: 10.1152/ajplung.00070.2010. View

19.

Chung A, Huang X, Meng X, Lan H . miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol. 2010; 21(8):1317-25. PMC: 2938591. DOI: 10.1681/ASN.2010020134. View

20.

Cutroneo K, White S, Phan S, Ehrlich H . Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol. 2007; 211(3):585-9. DOI: 10.1002/jcp.20972. View